EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Approved Nanomedicine against Diseases

Yuanchao Jia, Yuxin Jiang, Yonglong He, Wanting Zhang, Jiahui Zou, Kosheli Thapa Magar, Hamza Boucetta, Chao Teng, Wei He iD

Pharmaceutics · 26.02.2023 · 15 (3) · 774

DOI: 10.3390/pharmaceutics15030774 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.02.2023. Verfasst von Yuanchao Jia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Vtrying Pharmatech Co., Ltd., Nanjing 211122, China. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomedicine is a branch of medicine using nanotechnology to prevent and treat diseases. Nanotechnology represents one of the most effective approaches in elevating a drug‘s treatment efficacy and reducing toxicity by improving drug solubility, altering biodistribution, and controlling the release. The development of nanotechnology and materials has brought a profound revolution to medicine, significantly affecting the treatment of various major diseases such as cancer, injection, and cardiovascular diseases. Nanomedicine has experienced explosive growth in the past few years. Although the clinical transition of nanomedicine is not very satisfactory, traditional drugs still occupy a dominant position in formulation development, but increasingly active drugs have adopted nanoscale forms to limit side effects and improve efficacy. The review summarized the approved nanomedicine, its indications, and the properties of commonly used nanocarriers and nanotechnology.

Schlagwörter

Stichwörter der Autor:innen

cancercardiovascular diseaseinfectionliposomesnanocrystalnanomedicinepolymeric nanoparticles

Autor:innen und Institutionen

  • Nanjing Vtrying Pharmatech Co., Ltd., Nanjing 211122, China.
  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.

ORCID-Profile: Wei He

Förderung

  • National Natural Science Foundation of China
  • Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine

Zitieren

APA

Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023). Approved Nanomedicine against Diseases. Pharmaceutics, 15(3), 774. https://doi.org/10.3390/pharmaceutics15030774

Vancouver

Jia Y, Jiang Y, He Y, Zhang W, Zou J, Magar KT, et al. Approved Nanomedicine against Diseases. Pharmaceutics. 2023;15(3):774. doi:10.3390/pharmaceutics15030774

BibTeX
@article{Jia2023,
  author = {Jia, Yuanchao and Jiang, Yuxin and He, Yonglong and Zhang, Wanting and Zou, Jiahui and Magar, Kosheli Thapa and Boucetta, Hamza and Teng, Chao and He, Wei},
  title = {Approved Nanomedicine against Diseases},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {774},
  doi = {10.3390/pharmaceutics15030774}
}
Kostenlos starten →